Answers are grounded in this paper and cite their sources.
Evaluates BTK inhibitor effects on CAR T-cell function in mantle cell lymphoma, suggesting improved outcomes.
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma characterized by overexpression of cyclin D1 [ 1 ]. BTK inhibition and CD19-directed chimeric antigen receptor (CAR) T-cell therapy have achieved substantial efficacy. However, MCL frequently relapses, due to therapy resistance, immune escape, and failure of adoptive cell therapies [ 2 ]. Covalent irreversible BTK inhibitors including ibrutinib (IBN) have been shown to enhance immune responses and CAR T-cell effector function [ 2 , 3 , 4 , 5 ]. however, whether non-covalent BTK inhibitors exerts similar effects remains unknown. Pirtobrutinib (PBN), a selective non-covalent and reversible BTK inhibitor [ 6 ] has been approved by US FDA and used to treat relapsed MCL [ 7 ]. Clinically bridging with PBN prior to CAR T-cell therapy has been associated with enhanced CAR T-cell expansion, reduced exhaustion, a favorable cytokine profile, and high response rates [ 8 ]. However, direct preclinical evidence supporting these observations has been lacking. Here, we examined whether BTK inhibitor exposure during CAR T-cell manufacturing and in combination with CAR T-cell therapy reshapes stemness- and memory-associated transcriptional programs to promote naïve and stem-like T-cell properties, and whether this enhances metabolic fitness, persistence, and function while mitigating tumor microenvironment (TME)-driven immune dysfunction. To evaluate the effect of BTK inhibition on T‑cell properties and persistence, we re-analyzed a previously generated single‑cell RNA‑seq dataset from a cohort of patients before and after PBN treatment, and revealed a trend toward increased representation of naïve‑like and early activated CD8⁺ T cells, along with higher total T‑cell abundance, in PBN‑treated patients compared with PBN‑naïve individuals (Fig. 1A ; Supplementary Fig. 1 ). Consistently, transcripts encoding key T-cell stemness markers, including CD62L and IL7R, were upregulated in T cells from MCL patients following PBN treatment (Fig. 1B ). These results indicate that PBN promotes a stem-like memory T (T SCM ) cell phenotype and increases their frequency, positioning them to counteract declines in T‑cell activity and the development of exhaustion that limit CAR T‑cell and antibody‑based therapies, owing to their superior persistence and reduced susceptibility to exhaustion [ 9 ]. Fig. 1: Ex vivo pharmacologic conditioning with BTK inhibition promotes a naïve‑like, stem‑like memory phenotype and enhances metabolic fitness in CD19‑CAR T cells. Full size image A Proportions of T-cell subsets in samples from MCL patients before and after PBN treatment were derived from immune profiling of an available scRNA-seq dataset. Absolute T-cell counts of the T-cell subsets are calculated and presented as stacked bar plots. Color represents T-cell functional states. B Differentially expressed genes of stem-like memory T-cell markers (SELL, IL7R) and the persistence-associated molecule LTB in T cells from MCL patients were identified from scRNA-seq data and visualized in the plot. Dot size indicates the magnitude of differential expression (log fold-change, post-PBN vs. pre-PBN), while dot color represents statistical significance (-log10 FDR). C Relative percentages of naïve and stem-memory cell subsets in PBN plus dasatinib-modulated CAR T cells were quantified by flow cytometry. D Transcript levels of genes encoding memory and stemness regulators or markers (TCF7, LEF1, IL7R, BACH2, and CD62L) in the above CAR T cells was quantified by RT-qPCR analysis and presented as fold changes relative to their conventional counterparts. E Glucose uptake in conventional CD19-CAR T cells treated with PBN (0.2 and 1 μM) was assessed using 2-NBDG-incorporated flow cytometry. F Oxygen consumption rate in conventional CD19-CAR T cells was measured using a Seahorse XF96 Metabolic Flux Analyzer. G Target-specific secretion of IFN- γ and TNF-α in the supernatants of co-cultures with KI-modulated CAR T cells was quantified using BD OptEIA Human IFN-γ and TNF ELISA Kit. H Tumoricidal activity of KI-modulated CAR T cells in the presence or absence of PBN was evaluated in JeKo-BTK KD and Maver-1 cell lines, respectively. I Tumoricidal activity of conventional or KI-modulated CD19-CAR T cells in the presence or absence of PBN, was evaluated in primary cells from a patient who relapsed after CAR T-cell therapy. P value: * P < 0.05; ** P < 0.01; *** P < 0.001. To improve functional potency, durability, and metabolic fitness [ 10 , 11 , 12 ]. we generated CD19-directed CAR T cells by incorporating BTK inhibitors (IBN or PBN) during T-cell activation and transduction, and early expansion, in parallel with a conventional CAR T-cell manufacturing approach. Immune phenotyping of the kinase-inhibitor-conditioned CAR T cells (hereafter termed KI‑modulated CAR T cells) revealed that BTKi-integrated pharmacological modulation promoted a less differentiated and early‑memory state, with naïve‑like characteristics, compared with untreated controls. This was evidenced by significantly elevated proportions of CD45RA + CCR7 + , CD62L + CCR7 + , and IL-7 receptor alpha (CD127 + ) T cells (Supplementary Fig. 2A, B ), which are markers associated with T SCM and central memory T cells. These cells also expressed elevated levels of T cell activation markers (CD69, CD38, CD71) (Supplementary Fig. 2C ), indicating preserved activation capacity. Intriguingly, conditioning with the reversible BTK inhibitor PBN within our experimental setting, promoted a T SCM -like memory phenotype, marked by a pronounced increase in the proportion of CD45RA⁺CCR7⁺ naïve T cells within the CAR T-cell compartment (Fig. 1C ). Aligned with these phenotypic changes, RT-qPCR analysis revealed that exposure to PBN upregulated transcriptional programs associated with memory and stemness status, evidenced by significantly increased expression of TCF7, LEF1, IL7R, BACH2, and CD62L in the KI-modulated CD19-CAR T cells compared with their conventional counterparts (Fig. 1D ). Given the interplay between stemness and metabolic fitness, PBN exposure reduced glucose uptake in conventional CD19-CAR T cells (Fig. 1E ), while markedly enhancing mitochondrial respiratory capacity, including increased basal, ATP-coupled, and reserved oxygen consumption rates (Fig. 1F ), suggesting a metabolic shift from glycolysis toward oxidative phosphorylation, indicative of an adaptation typical of T SCM cells [ 13 ]. A similar metabolic modulatory effect was observed with IBN treatment (Supplementary Fig. 2D, E ). Concordantly, these attributes define a less differentiated, metabolically resilient CAR T-cell population with enhanced persistence and functional capacity. Although the precise mechanism by which PBN preserves a T SCM -like phenotype remains to be fully elucidated, our findings are consistent with a model in which low dose, highly selective BTK inhibition modestly attenuates TCR/CAR signaling and promotes metabolic fitness. We next assessed the effector function of KI‑modulated CD19-CAR T cells with or without PBN exposure. Comparable to their conventional counterparts, while coculture of the CD19-CAR T cells with target cells preserved the ability to induce target-specific secretion of IFN-γ and TNF-α, the addition of PBN further enhanced this response (Fig. 1G ). The increase in the effector molecules was accompanied by a robust cytotoxic response against target cells within 24 h of co-culture (Fig. 1H ), compared to a basal level in cultures lacking effector cells. Notably, KI-modulated CAR T-cell products consistently displayed augmented effector responses against primary MCL cells from patients who relapsed after CAR T-cell therapy and strikingly, they demonstrated more pronounced tumoricidal activity than conventional CAR T cells (Fig. 1I ). Collectively, integrating KI-mediated modulation into CAR T-cell generation or combining conventional CAR T cells with PBN, represents a practical strategy for achieving potent and durable therapeutic efficacy. This approach addresses a critical challenge observed in non-responders, where an immune-suppressive TME constitutes a hostile barrier to immune functionality. To recapitulate the interaction between the immune compartment and tumor cells in an in vivo context, we employed a newly developed TME-mimicking model. This system comprised tumor cells and a multicellular immune compartment isolated from healthy donors or MCL patients, co-cultured on a monolayer of lymph node stromal cells from a CD40L/IL-21-expressing line YK6 and supplemented with key cytokines [ 14 ]. Co-culture of KI-modulated CD19-CAR T cells with CD19 + JeKo-BTK KD and Maver-1 cells resulted in elevated IL-10 secretion, a cytokine commonly associated with regulatory T-cell responses, denoting a potential role for MCL tumor cells in promoting immune suppression. Notably, the induction was markedly reduced by addition of low-dose PBN (1 µM) (Supplementary Fig. 3A ). Encounter with target cells markedly induced secretion of both IFN-γ and TNF-α, whereas the addition of PBN did not significantly alter the induction (Supplementary Fig. 3B, C ). Consistently, treatment with PBN (0.2 µM and 1 µM) significantly enhanced the tumoricidal activity of the CD19-CAR T cells at an effector-to-target ratio of 1:1, whereas PBN alone exhibited no significant cytotoxicity (Supplementary Fig. 3D, E ). Of note, PBN was used at low to submicromolar concentrations (0.2–1 μM), a range reported to retain BTK selectivity with minimal or no off-target inhibitory effects on ITK, a kinase that is directly inhibited by IBN. To determine whether our in vitro observations are recapitulated in vivo, we next evaluated the effect of PBN on the antitumor efficacy of CD19-CAR T cells in preclinical mouse models. CD19-positive MCL cell line-derived (CDX) and patient-derived (PDX) xenograft models exhibiting diverse therapeutic response profiles were established in-house using NSG mice [ 15 ]. We first generated a CDX model using CD19 high Maver-1 cell line. After tumor engraftment, mice were reconstituted with KI-modulated CD19-CAR T cells at an E:T ratio of 1 or 2. To evaluate the effect of PBN on the in vivo antitumor activity of the CD19‑CAR T‑cells, designated cohorts received a low, non-cytotoxic dose of PBN (25 mg/kg). Consistent with its proposed role as a CAR T‑cell modulator, PBN administration resulted in markedly enhanced tumor control and prolonged mouse survival relative to control groups (Fig. 2A, B ; Supplementary Fig. 4 ). Importantly, quantification of total T cells in dissected mouse tissues at the study endpoint revealed a significant increase in the PBN-treated groups compared with the CAR T-cell only group (Fig. 2C ), supporting a role for PBN in enhancing CAR T-cell expansion and persistence in vivo. PDX models derived from primary MCL specimens are expected to faithfully recapitulate the treatment response and immune dynamics. Therefore, we established PDX models using primary specimens from MCL patients who had relapsed following CD19-CAR T cell therapy, representing resistance profiles observed in real-world clinical settings. Strikingly, incorporating PBN with CD19-CAR T cells elicited robust antitumor activity in these CAR T-relapsed PDX models. This was evidenced by pronounced suppression of tumor growth and significant extension of survival (Fig. 2D, E ). We further validated the antitumor efficacy of the CD19‑CAR T‑cell therapy with PBN as an immunomodulatory adjunct, using a PDX model derived from a CAR T-relapsed MCL patient and harbored ATM mutations and TP53 exon 7 deletion. Consistent with prior observations, the addition of PBN significantly enhanced tumor suppression, leading to more pronounced inhibition of tumor growth and extended survival (Fig. 2F, G ). As TP53 mutations are associated with immune evasion and CAR T therapy resistance, our findings support a role for PBN-mediated modulation in overcoming CAR T‑cell resistance in MCL. Given the clinical relevance of these PDX models, this combination offers a promising strategy to improve outcomes in patients with relapsed/refractory MCL. Fig. 2: Subcytotoxic BTK Inhibition enhances antigen-dependent effector functions and potentiates tumor rejection by CD19-directed CAR T cells in MCL. Full size image BTKi impact on CD-19 CAR T-mediated anti-MCL efficacy was evaluated in MCL CDX and PDX models. A A CDX model was established by implanting NSG mice with luciferase-expressing Maver-1 cells. Specified tumor-bearing mice were reconstituted with KI-modulated CD19-CAR T cells and treated with PBN (25 mg/kg). Tumor progression was monitored via bioluminescent imaging (BLI), and tumor growth over time was quantified by measuring the average radiance and plotting it longitudinally. B The overall survival of the treated mice in CDX model was assessed using Kaplan-Meier curves (GraphPad Prism 10, Dotmatics), with statistical significance determined by the Log-rank (Mantel-Cox) test across all models in this study. C Total T cells were counted using flow cytometry in the dissected mouse tissues (blood, spleen, liver, and bone marrow) at the endpoint, shown as relative counts. D A PDX model was established by implanting NSG mice with CD19-expressing tumor cells (1 ×10 6 / mouse) from an MCL patient who relapsed after CAR T-cell therapy. Designated tumor-bearing mice were reconstituted with KI-modulated CD19-CAR T cells at the effector-to- target ratios of 1:1 and 2:1, respectively, and subsequently treated with PBN (25 mg/kg). Tumor progression was monitored via plasma beta-2 microglobulin (B2M) quantification. E, G The overall survival of the treated mice in panels D and F was assessed using Kaplan-Meier curves, as described above. F A PDX model was established as described above from a patient who relapsed after CAR T-cell therapy and harbored ATM and TP53 mutations, and subsequently treated with PBN (25 mg/kg). Tumor growth was monitored as described above. P value: * P < 0.05; ** P < 0.01; *** P < 0.001. In summary, reversible and irreversible BTK inhibition promotes naïve and stem-like T-cell properties in CD19-CAR T cells while enhancing their metabolic fitness and persistence. Moreover, consistent with prior observations from IBN, PBN treatment augments antigen‑specific effector function and antitumor activity, leading to improved tumor rejection in MCL. Collectively, these findings demonstrate that, at non-cytotoxic doses, BTK inhibition acts in concert with CD19‑CAR T cell therapy to enhance efficacy across diverse MCL settings, including disease resistant to BTK inhibition or refractory to prior CAR T‑cell therapy.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: